119870-76-7

Basic information

• Product Name: (E)-ethyl 2-methyl-3-(3-nitrophenyl)acrylate
• Synonyms: (E)-ethyl 2-methyl-3-(3-nitrophenyl)acrylate
• CAS NO: 119870-76-7
• Molecular Weight: 235.24
• Mol File: 119870-76-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (E)-ethyl 2-methyl-3-(3-nitrophenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-ethyl 2-methyl-3-(3-nitrophenyl)acrylate(119870-76-7)
• EPA Substance Registry System: (E)-ethyl 2-methyl-3-(3-nitrophenyl)acrylate(119870-76-7)

Safety Data

• Hazardous Substances Data: 119870-76-7(Hazardous Substances Data)

Upstream product

• 64-17-5 ethanol 
• 124525-54-8 2-methyl-3-(3-nitrophenyl)propenoic acid 
• 99-61-6 3-nitro-benzaldehyde 
• 627882-12-6 ethyl 2-(hydroxy(3-nitrophenyl)methyl)acrylate 

Downstream Products

• 1261078-82-3 (E)-2-methyl-3-(3-(quinoxalin-3-ylamino)phenyl)acrylic acid 
• 216576-08-8 (E)-ethyl 3-(3-aminophenyl)-2-methylacrylate 

Relevant articles and documents

Design and synthesis of small molecule RhoA inhibitors: A new promising therapy for cardiovascular diseases?

RhoA is a member of Rho GTPases, a subgroup of the Ras superfamily of small GTP-binding proteins. RhoA, as an important regulator of diverse cellular signaling pathways, plays significant roles in cytoskeletal organization, transcription, and cell-cycle progression. The RhoA/ROCK inhibitors have emerged as a new promising treatment for cardiovascular diseases. However, to date, RhoA inhibitors are macromolecules, and to our knowledge, small molecular-based inhibitors have not been reported. In this study, a series of first-in-class small molecular RhoA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. Virtual screening of ～200,000 compounds, followed by SPR-based binding affinity assays resulted in three compounds with binding affinities to RhoA at the micromolar level (compounds 1-3). Compound 1 was selected for further structure modifications in considering binding activity and synthesis ease. Fourty-one new compounds (1, 12a-v, 13a-h, and 14a-j) were designed and synthesized accordingly. It was found that eight (12a, 12j, 14a, 14b, 14d, 14e, 14 g, and 14h) showed high RhoA inhibition activities with IC50 values of 1.24 to 3.00 μM. A pharmacological assay indicated that two compounds (14g and 14 h) demonstrated noticeable vasorelaxation effects against PE-induced contraction in thoracic aorta artery rings and served as good leads for developing more potent cardiovascular agents.

Carboxamide compounds as SRS-A antagonists

The compounds of the invention are certain new propenamides and 2-butenamides having a (carboxyalkanamido)phenyl or a (carboxyalkenamido)phenyl group at the 3-position, and certain esters thereof, and certain cyclopropanecarboxamide compounds having a (ca

(Carboxy-oxo-pyrrolidino)phenylalkenamides and esters thereof as SRS-A antagonists

Certain new propenamide and 2-butenamide compounds, having a (4-carboxy-2-oxo-pyrrolidino)phenyl substituent at the 3-position, and certain esters thereof, and their use for antagonizing the spasmogenic activity of slow-reacting substance of anaphylaxis (